Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study.

作者：Ruinuo Jia, Junqian Zhang, Yaowen Zhang, Shuoguo Li, Jianguang Ma, Jun Yao, Hong Ge, Kefeng Guo, Jingxia Li, Chuntao Tian, Zhiwei Chang, Xiaobing Chen, Jianzheng Wang, Xiaohong Wang, Anping Zheng, Manxi Sheng, Liuyan Li, Lei Ni, Shegan Gao · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco.2025.43.16_suppl.e16143 · 研究领域：Esophageal Cancer Research and Treatment、Gastric Cancer Management and Outcomes、Pancreatic and Hepatic Oncology Research

e16143 Background: Local recurrence is the main failure pattern after radical treatment of esophageal cancer. There is no uniform treatment specification for such patients(pts) so far. The combination of immune checkpoint inhibitors and concurrent chemoradiotherapy (CCRT) has emerged as a novel strategy to treat esophageal cancer. This research was to evaluate the efficacy and safety of camrelizumab (ICI targeting PD-1) combined with CCRT in the treatment of locally recurrent esophageal cancer. Methods: This open clinical study planned to enroll 62 pts with locally recurrent esophageal cancer following radical treatment who aged 18-75 years with ECOG performance status of 0-1. Pts received the following treatments: camrelizumab (200 mg q2w, continuous medication until disease progression, intolerable toxicity, or withdrawal); simultaneous radiotherapy (the total radiation dose was 50-50.4 Gy, which was given by 25-28 fractions, 5 fractions per week, with 1.8-2 Gy for each fraction); chemotherapy (capecitabine, 625mg/m 2 , bid, oral, d1-5, qw, total 5 weeks). The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR) ,disease control rate (DCR), and safety. Results: Between Feb 2022 and Jan 2025, 35 pts with a median age of 65 years old had been enrolled. Among the evaluable pts, the ORR was 58.6% (17/29), the DCR was 86.2% (25/29). With a median follow-up of 18.0 months (95% CI 6.8-29.2), the med...